Clinilabs, the US-based contract research organisation (CRO) focused on early-phase and speciality drug development services, has opened a Phase I unit in Eatontown, New Jersey.
The new 50-bed, 15,000 sq ft Specialty Pharma Phase I Unit features semi-private and examination rooms, a large pharmacokinetic sampling facility, a bioanalytic laboratory and a pharmacy. It expands on the services currently offered at Clinilabs’ 50-bed Phase I unit in Manhattan, New York.
“This unit allows us to expand our Phase I capacity in two locations, providing first-in-human through end-of-phase II CRO services to our clients,” commented president and chief executive officer Gary Zammit. “We are now able to enrol larger samples of normal healthy volunteers and patient populations at our two units and at investigator sites worldwide.”